Skip to main content

Advertisement

SpringerLink
Log in

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms

  • Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

This review article provides a brief overview of the new WHO classification by adopting a question–answer model to highlight the spectrum of head and neck neuroendocrine neoplasms which includes epithelial neuroendocrine neoplasms (neuroendocrine tumors and neuroendocrine carcinomas) arising from upper aerodigestive tract and salivary glands, and special neuroendocrine neoplasms including middle ear neuroendocrine tumors (MeNET), ectopic or invasive pituitary neuroendocrine tumors (PitNET; formerly known as pituitary adenoma) and Merkel cell carcinoma as well as non-epithelial neuroendocrine neoplasms (paragangliomas). The new WHO classification follows the IARC/WHO nomenclature framework and restricts the diagnostic term of neuroendocrine carcinoma to poorly differentiated epithelial neuroendocrine neoplasms. In this classification, well-differentiated epithelial neuroendocrine neoplasms are termed as neuroendocrine tumors (NET), and are graded as G1 NET (no necrosis and < 2 mitoses per 2 mm2; Ki67 < 20%), G2 NET (necrosis or 2–10 mitoses per 2 mm2, and Ki67 < 20%) and G3 NET (> 10 mitoses per 2 mm2 or Ki67 > 20%, and absence of poorly differentiated cytomorphology). Neuroendocrine carcinomas (> 10 mitoses per 2 mm2, Ki67 > 20%, and often associated with a Ki67 > 55%) are further subtyped based on cytomorphological characteristics as small cell and large cell neuroendocrine carcinomas. Unlike neuroendocrine carcinomas, head and neck NETs typically show no aberrant p53 expression or loss of RB reactivity. Ectopic or invasive PitNETs are subtyped using pituitary transcription factors (PIT1, TPIT, SF1, GATA3, ER-alpha), hormones and keratins (e.g., CAM5.2). The new classification emphasizes a strict correlation of morphology and immunohistochemical findings in the accurate diagnosis of neuroendocrine neoplasms. A particular emphasis on the role of biomarkers in the confirmation of the neuroendocrine nature of a neoplasm and in the distinction of various neuroendocrine neoplasms is provided by reviewing ancillary tools that are available to pathologists in the diagnostic workup of head and neck neuroendocrine neoplasms. Furthermore, the role of molecular immunohistochemistry in the diagnostic workup of head and neck paragangliomas is discussed. The unmet needs in the field of head and neck neuroendocrine neoplasms are also discussed in this article. The new WHO classification is an important step forward to ensure accurate diagnosis that will also form the basis of ongoing research in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol. 2011;24:S53–7.

    CAS  PubMed  Google Scholar 

  2. Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem. 1969;17:303–13.

    CAS  PubMed  Google Scholar 

  3. Fontaine J, Le Douarin NM. Analysis of endoderm formation in the avian blastoderm by use of quail-chick chimeras. The problem of the neuroectodermal origin of the cells of the APUD series. J Embryol Exp Morphol. 1977;41:209–22.

    CAS  PubMed  Google Scholar 

  4. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol. 1907;1:426–32.

    Google Scholar 

  5. Gosset A, Masson P. Tumeurs endocrines de lappendice. Presse Med. 1914;25:237–40.

    Google Scholar 

  6. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;281:238–9.

    Google Scholar 

  7. Gould VE, Memoli VA, Dardi LE. Multidirectional differentiation in human epithelial cancers. J Submicrosc Cytol. 1981;13:97–115.

    Google Scholar 

  8. Liebow A. Tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology; 1952.

    Google Scholar 

  9. Bensch KG, Corrin B, Pariente R, Spencer H. Oat-cell carcinoma of the lung: its origin and relationship to bronchial carcinoid. Cancer. 1968;22:1163–72.

    CAS  PubMed  Google Scholar 

  10. Goodner JT, Berg JW, Watson WL. The nonbenign nature of bronchial carcinoids and cylindromas. Cancer. 1961;14:539–46.

    CAS  PubMed  Google Scholar 

  11. Arrigoni MG, Woolner LB, Bernatz PR. Atypical carcinoid of the lung. J Thorac Cardiovasc Surg. 1972;64:413–21.

    CAS  PubMed  Google Scholar 

  12. Gould VE, Linnoila I, Memoli VA, Warren WH. Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 1983;18:287–330.

    PubMed  Google Scholar 

  13. Wenig BM, Hyams VJ, Heffner DK. Moderately differentiated neuroendocrine carcinoma of the larynx: a clinicopathologic study of 54 cases. Cancer. 1988;62:2658–76.

    CAS  PubMed  Google Scholar 

  14. Mills SE. Neuroectodermal neoplasms of the head and neck with special emphasis on neuroendocrine carcinomas. Mod Pathol. 2002;15:264–78.

    PubMed  Google Scholar 

  15. Lewis JS Jr, Spence DC, Chiosea S, et al. Large cell neuroendocrine carcinoma of the larynx: definition of an entity. Head Neck Pathol. 2010;4:198–207.

    PubMed  PubMed Central  Google Scholar 

  16. Lewis JS Jr, Ferlito A, Gnepp DR, et al. Terminology and classification of neuroendocrine neoplasms of the larynx. Laryngoscope. 2011;121:11897–21193.

    Google Scholar 

  17. Perez-Ordonez B, et al. WHO classification of head & neck tumours. IARC: Lyon; 2017. p. 95–8.

    Google Scholar 

  18. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770–86.

    PubMed  PubMed Central  Google Scholar 

  19. Rindi G, Inzani F. Neuroendocrine neoplasm: update: toward universal nomenclature. Endocr Relat Cancer. 2020;27:R211–8.

    CAS  PubMed  Google Scholar 

  20. Klimstra DS, Modlin IR, Adsay V, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300–13.

    PubMed  Google Scholar 

  21. WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 9). https://publications.iarc.fr/

  22. Agaimy A, Jain D, Uddin N, Rooper LM, Bishop JA. SMARCA4-deficient sinonasal carcinoma: a series of 10 cases expanding the genetic spectrum of SWI/SNF-driven sinonasal malignancies. Am J Surg Pathol. 2020;44(5):703–10.

    PubMed  Google Scholar 

  23. Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers. Cancer Cytopathol. 2016;124:871–84.

    PubMed  Google Scholar 

  24. Rooper LM, Bishop JA, Westra WH. INSM1 is a sensitive and specific marker of neuroendocrine differentiation in head and neck tumors. Am J Surg Pathol. 2018;42:665–71.

    PubMed  Google Scholar 

  25. La Rosa S. Challenges in high-grade neuroendocrine neoplasms and mixed neuroendocrine/non-neuroendocrine neoplasms. Endocr Pathol. 2021;32:245–57.

    PubMed  PubMed Central  Google Scholar 

  26. Juhlin CC, Zedenius J, Höög A. Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin. Endocr Pathol. 2020;31:401–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Strojan P, Šifrer R, Ferlito A, Grašič-Kuhar C, Lanišnik B, Plavc G, Zidar N. Neuroendocrine carcinoma of the larynx and pharynx: a clinical and histopathological study. Cancers (Basel). 2021;13:4813.

    CAS  Google Scholar 

  28. Juhlin CC. Challenges in paragangliomas and pheochromocytomas: from histology to molecular immunohistochemistry. Endocr Pathol. 2021;32:228–44.

    PubMed  PubMed Central  Google Scholar 

  29. Hayashi T, Mete O. Head and neck paragangliomas: what does the pathologist need to know? Diagn Histopathol. 2014;20:316–25.

    Google Scholar 

  30. Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol. 2018;31:900–9.

    CAS  PubMed  Google Scholar 

  31. Mete O, Kefeli M, Çalışkan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol. 2019;32:484–9.

    CAS  PubMed  Google Scholar 

  32. Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ. Utility of GATA-3 expression in the analysis of pituitary neuroendocrine tumour (PitNET) transcription factors. Endocr Pathol. 2020;31:150–5.

    PubMed  Google Scholar 

  33. Kimura N, Shiga K, Kaneko K, Sugisawa C, Katabami T, Naruse M. The diagnostic dilemma of GATA3 immunohistochemistry in pheochromocytoma and paraganglioma. Endocr Pathol. 2020;31:95–100.

    CAS  PubMed  Google Scholar 

  34. Asa SL, Ezzat S, Mete O. The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med. 2018;7:280.

    CAS  PubMed Central  Google Scholar 

  35. Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol. 1999;21:16–20.

    CAS  PubMed  Google Scholar 

  36. Miner AG, Patel RM, Wilson DA, Procop GW, Minca EC, Fullen DR, Harms PW, Billings SD. Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus. Mod Pathol. 2015;28:498–504.

    CAS  PubMed  Google Scholar 

  37. Mete O, Asa SL. Structure, function, and morphology in the classification of pituitary neuroendocrine tumors: the importance of routine analysis of pituitary transcription factors. Endocr Pathol. 2020;31:330–6.

    PubMed  Google Scholar 

  38. Asa SL, Mete O. Immunohistochemical biomarkers in pituitary pathology. Endocr Pathol. 2018;29:130–6.

    CAS  PubMed  Google Scholar 

  39. Yan M, Roncin KL, Wilhelm S, Wasman JK, Asa SL. Images in endocrine pathology: high-grade intrathyroidal parathyroid carcinoma with Crooke’s hyalinization. Endocr Pathol. 2020;31:190–4.

    PubMed  Google Scholar 

  40. Bal M, Sharma A, Rane SU, et al. Neuroendocrine neoplasms of the larynx: a clinicopathologic analysis of 27 neuroendocrine tumors and neuroendocrine carcinomas. Head Neck Pathol. 2021. https://doi.org/10.1007/s12105-021-01367-9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kao HL, Chang WC, Li WY, Chia-Heng Li A, Fen-Yau LA. Head and neck large cell neuroendocrine carcinoma should be separated from atypical carcinoid on the basis of different clinical features, overall survival, and pathogenesis. Am J Surg Pathol. 2012;36:185–92.

    PubMed  Google Scholar 

  42. Dogukan FM, Yilmaz Ozguven B, Dogukan R, Kabukcuoglu F. Comparison of monitor-image and printout-image methods in Ki-67 scoring of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol. 2019;30:17–23.

    CAS  PubMed  Google Scholar 

  43. Alos L, Hakim S, Larque AB, et al. p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. Virchows Arch. 2016;469:277–84.

    CAS  PubMed  Google Scholar 

  44. Halmos GB, van der Laan TP, van Hemel BM, et al. human papillomavirus involved in laryngeal neuroendocrine carcinoma? Eur Arch Otorhinolaryngol. 2013;270:719–25.

    PubMed  Google Scholar 

  45. Uccella S, La Rosa S, Volante M, Papotti M. Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol. 2018;29:150–68.

    PubMed  Google Scholar 

  46. Uccella S, La Rosa S, Metovic J, et al. Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites. Endocr Pathol. 2021;32(1):192–210.

    PubMed  Google Scholar 

  47. Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and predictive role of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms. Endocr Pathol. 2021;32:309–17.

    CAS  PubMed  Google Scholar 

  48. Li B, Li X, Mao R, Liu M, Fu L, Shi L, Zhao S, Fu M. Overexpression of ODF1 in gastrointestinal tract neuroendocrine neoplasms: a novel potential immunohistochemical biomarker for well-differentiated neuroendocrine tumors. Endocr Pathol. 2021;32:301–8.

    CAS  PubMed  Google Scholar 

  49. Dandpat SK, Rai SKR, Shah A, Goel N, Goel AH. Silent stellate ganglion paraganglioma masquerading as schwannoma: a surgical nightmare. J Craniovertebr Junction Spine. 2020;11:240–2.

    PubMed  PubMed Central  Google Scholar 

  50. Seth R, Ahmed M, Hoschar AP, Wood BG, Scharpf J. Cervical sympathetic chain paraganglioma: a report of 2 cases and a literature review. Ear Nose Throat J. 2014;93:E22-27.

    PubMed  Google Scholar 

  51. Cadiñanos J, Llorente JL, de la Rosa J, et al. Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. Head Neck. 2011;33:1233–40.

    PubMed  Google Scholar 

  52. Moyer JS, Bradford CR. Sympathetic paraganglioma as an unusual cause of Horner’s syndrome. Head Neck. 2001;23:338–42.

    CAS  PubMed  Google Scholar 

  53. Erickson LA, Mete O. Immunohistochemistry in diagnostic parathyroid pathology. Endocr Pathol. 2018;29:113–29.

    CAS  PubMed  Google Scholar 

  54. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med. 2008;132:1272–84.

    PubMed  Google Scholar 

  55. Osinga TE, Korpershoek E, de Krijger RR, et al. Catecholamine-synthesizing enzymes are expressed in parasympathetic head and neck paraganglioma tissue. Neuroendocrinology. 2015;101:289–95.

    CAS  PubMed  Google Scholar 

  56. Kimura N. Dopamine β-hydroxylase: an essential and optimal immunohistochemical marker for pheochromocytoma and sympathetic paraganglioma. Endocr Pathol. 2021;32:258–61.

    CAS  PubMed  Google Scholar 

  57. Kimura N, Shiga K, Kaneko KI, et al. Immunohistochemical expression of choline acetyltransferase and catecholamine-synthesizing enzymes in head-and-neck and thoracoabdominal paragangliomas and pheochromocytomas. Endocr Pathol. 2021;32:442–51.

    CAS  PubMed  Google Scholar 

  58. Zhou YY, Coffey M, Mansur D, et al. Images in endocrine pathology: progressive loss of sustentacular cells in a case of recurrent jugulotympanic paraganglioma over a span of 5 years. Endocr Pathol. 2020;31:310–4.

    PubMed  Google Scholar 

  59. Delfin L, Mete O, Asa SL. Follicular cells in pituitary neuroendocrine tumors. Hum Pathol. 2021;114:1–8.

    CAS  PubMed  Google Scholar 

  60. Powers JF, Tischler AS. Immunohistochemical staining for SOX10 and SDHB in SDH-deficient paragangliomas indicates that sustentacular cells are not neoplastic. Endocr Pathol. 2020;31:307–9.

    CAS  PubMed  Google Scholar 

  61. Mete O, Hannah-Shmouni F, Kim R, Stratakis CA. Inherited neuroendocrine neoplasms. In: Asa SL, La Rosa SL, Mete O, editors. The spectrum of neuroendocrine neoplasia. Springer: Cham; 2021. p. 409–59.

    Google Scholar 

  62. Oudijk L, Gaal J, de Krijger RR. The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes. Endocr Pathol. 2019;30:64–73.

    CAS  PubMed  Google Scholar 

  63. Papathomas TG, Suurd DPD, Pacak K, et al. What have we learned from molecular biology of paragangliomas and pheochromocytomas? Endocr Pathol. 2021;32:134–53.

    PubMed  Google Scholar 

  64. Duan K, Mete O. Hereditary endocrine tumor syndromes: the clinical and predictive role of molecular histopathology. AJSP Rev Rep. 2017;22(5):246–68.

    Google Scholar 

  65. Mete O, Pakbaz S, Lerario AM, Giordano TJ, Asa SL. Significance of alpha-inhibin expression in pheochromocytomas and paragangliomas. Am J Surg Pathol. 2021;45:1264–73.

    PubMed  Google Scholar 

  66. Favier J, Meatchi T, Robidel E, et al. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol. 2020;33(1):57–64.

    CAS  PubMed  Google Scholar 

  67. Udager AM, Magers MJ, Goerke DM, et al. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2018;71:47–54.

    CAS  PubMed  Google Scholar 

  68. Kimura N, Takayanagi R, Takizawa N, et al. Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405–14.

    PubMed  Google Scholar 

  69. Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474:721–34.

    CAS  PubMed  Google Scholar 

  70. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Hyams VJ, Michaels L. Benign adenomatous neoplasm (adenoma) of the middle ear. Clin Otolaryngol Allied Sci. 1976;1:17–26.

    CAS  PubMed  Google Scholar 

  72. Sandison A, Bell D, Thompson LDR. Middle ear adenoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head & neck tumours. IARC: Lyon; 2017. p. 272–3.

    Google Scholar 

  73. Saliba I, Evard AS. Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series. Cases J. 2009;2:6508–15.

    PubMed  PubMed Central  Google Scholar 

  74. Ramsey MJ, Nadol JB, Pilch BZ, et al. Carcinoid tumor of the middle ear: clinical features, recurrences, and metastases. Laryngoscope. 2005;115:1660–6.

    PubMed  Google Scholar 

  75. Torske KR, Thompson LD. Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature. Mod Pathol. 2002;15:543–55.

    PubMed  Google Scholar 

  76. Agaimy A, Lell M, Schaller T, et al. “Neuroendocrine” middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathol. 2015;66:182–91.

    Google Scholar 

  77. Asa SL, Arkun K, Tischler AS, et al. Middle ear “adenoma”: a neuroendocrine tumor with predominant L cell differentiation. Endocr Pathol. 2021;32:433–41.

    CAS  PubMed  Google Scholar 

  78. Lott Limbach AA, Hoschar AP, Thompson LD, et al. Middle ear adenomas stain for two cell populations and lack myoepithelial cell differentiation. Head Neck Pathol. 2012;6:345–53.

    PubMed  PubMed Central  Google Scholar 

  79. Zhu J, Wang Z, Zhang Y, et al. Ectopic pituitary adenomas: clinical features, diagnostic challenges and management. Pituitary. 2020;23:648–64.

    PubMed  Google Scholar 

  80. Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. Am J Surg Pathol. 2017;41:525–34.

    PubMed  Google Scholar 

  81. Rasmussen P, Lindholm J. Ectopic pituitary adenomas. Clin Endocrinol (Oxf). 1979;11:69–74.

    CAS  Google Scholar 

  82. Hodgson A, Pakbaz S, Shenouda C, Francis JA, Mete O. Mixed sparsely granulated lactotroph and densely granulated somatotroph pituitary neuroendocrine tumor expands the spectrum of neuroendocrine neoplasms in ovarian teratomas: the role of pituitary neuroendocrine cell lineage biomarkers. Endocr Pathol. 2020;31:315–9.

    PubMed  Google Scholar 

  83. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022. https://doi.org/10.1007/s12022-022-09703-7.

    Article  PubMed  Google Scholar 

  84. Asa SL. Challenges in the diagnosis of pituitary neuroendocrine tumors. Endocr Pathol. 2021;32:222–7.

    PubMed  Google Scholar 

  85. Asa SL, Mete O, Cusimano MD, et al. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol. 2021;34:1634–50.

    PubMed  Google Scholar 

  86. Saeger W, Mawrin C, Meinhardt M, et al. Two pituitary neuroendocrine tumors (PitNETs) with very high proliferation and TP53 mutation: high-grade PitNET or PitNEC? Endocr Pathol. 2021. https://doi.org/10.1007/s12022-021-09693-y.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Hodgson A, Pakbaz S, Tayyari F, Young JEM, Mete O. Diagnostic pitfall: parathyroid carcinoma expands the spectrum of calcitonin and calcitonin gene-related peptide expressing neuroendocrine neoplasms. Endocr Pathol. 2019;30:168–72.

    PubMed  Google Scholar 

  88. Feola T, Puliani G, Sesti F, et al. Laryngeal neuroendocrine tumor with elevated serum calcitonin: a diagnostic and therapeutic challenge. Case report and review of literature. Front Endocrinol (Lausanne). 2020;11:397.

    PubMed  PubMed Central  Google Scholar 

  89. Insabato L, De Rosa G, Terracciano LM, et al. A calcitonin-producing neuroendocrine tumor of the larynx: a case report. Tumori. 1993;79:227–30.

    CAS  PubMed  Google Scholar 

  90. Kuan EC, Alonso JE, Tajudeen BA, et al. Small cell carcinoma of the head and neck: a comparative study by primary site based on population data. Laryngoscope. 2017;127:1785–90.

    PubMed  Google Scholar 

  91. Ohmoto A, Sato Y, Asaka N, et al. Clinicopathologic and genomic features in patients with head and neck neuroendocrine carcinoma. Mod Pathol. 2021;34:1979–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Bishop JA, Westra WH. Human papillomavirus-related small cell carcinoma of the oropharynx. Am J Surg Pathol. 2011;35:1679–84.

    PubMed  PubMed Central  Google Scholar 

  93. van der Laan TP, Plaat BE, van der Laan BF, et al. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: a meta-analysis of 436 reported cases. Head Neck. 2015;37:707–15.

    PubMed  Google Scholar 

  94. Davies-Husband CR, Montgomery P, Premachandra D, et al. Primary, combined, atypical carcinoid and squamous cell carcinoma of the larynx: a new variety of composite tumour. J Laryngol Otol. 2010;124:226–9.

    CAS  PubMed  Google Scholar 

  95. Bonato M, Frigerio B, Capelia C, et al. Composite enteric-type adenocarcinoma-carcinoid of the nasal mucosa. Endocr Pathol. 1993;4:40–7.

    PubMed  Google Scholar 

  96. La Rosa S, Furlan D, Franzi F, et al. Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinic-pathologic and molecular study of a case and review of the literature. Head Neck Pathol. 2013;7:76–84.

    PubMed  Google Scholar 

  97. Wasserman JK, Papp S, Hope AJ, Perez-Ordóñez B. Epstein-Barr virus-positive large cell neuroendocrine carcinoma of the nasopharynx: report of a case with complete clinical and radiological response after combined chemoradiotherapy. Head Neck Pathol. 2018;12:587–91.

    PubMed  PubMed Central  Google Scholar 

  98. Cai Z, Lin M, Blanco AI, Liu J, Zhu H. Epstein-Barr virus-positive large cell neuroendocrine carcinoma of the nasopharynx: report of one case and review of the literature. Head Neck Pathol. 2019;13:313–7.

    PubMed  Google Scholar 

  99. La Rosa S, Bonzini M, Sciarra A, et al. Exploring the prognostic role of Ki67 proliferative index in Merkel cell carcinoma of the skin: clinico-pathologic analysis of 84 cases and review of the literature. Endocr Pathol. 2020;31:392–400.

    PubMed  PubMed Central  Google Scholar 

  100. Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol. 2017;137:819–27.

    CAS  PubMed  Google Scholar 

  101. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Wong SQ, Waldeck K, Vergara IA, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75:5228–34.

    CAS  PubMed  Google Scholar 

  103. Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2016;7:3403–15.

    PubMed  Google Scholar 

  104. Knepper TC, Montesion M, Russell JS, et al. The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019;25:5961–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Leblebici C, Yeni B, Savli TC, et al. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: evaluation of 24 cases. Ann Diagn Pathol. 2019;40:53–8.

    PubMed  Google Scholar 

  106. Kervarrec T, Tallet A, Miquelestorena-Standley E, et al. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas. Mod Pathol. 2019;32:499–510.

    CAS  PubMed  Google Scholar 

  107. Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology. 2020;76:251–64.

    PubMed  Google Scholar 

  108. Sauer CM, Haugg AM, Chteinberg E, et al. Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. Crit Rev Oncol Hematol. 2017;116:99–105.

    CAS  PubMed  Google Scholar 

  109. Hoang MP, Donizy P, Wu CL, et al. TdT expression is a marker of better survival in Merkel cell carcinoma, and expression of B-cell Markers is associated with Merkel cell polyomavirus. Am J Clin Pathol. 2020;154:38–47.

    CAS  PubMed  Google Scholar 

  110. Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23:3564–71.

    PubMed  PubMed Central  Google Scholar 

  111. Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133:642–6.

    CAS  PubMed  Google Scholar 

  112. Higaki-Mori H, Kuwamoto S, Iwasaki T, et al. Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma. Hum Pathol. 2012;43:2282–91.

    PubMed  Google Scholar 

  113. Fleming KE, Ly TY, Pasternak S, et al. Support for p63 expression as an adverse prognostic marker in Merkel cell carcinoma: report on a Canadian cohort. Hum Pathol. 2014;45:952–60.

    CAS  PubMed  Google Scholar 

  114. Ricci C, Morandi L, Ambrosi F, et al. Intron 4–5 hTERT DNA hypermethylation in Merkel cell carcinoma: frequency, association with other clinico-pathological features and prognostic relevance. Endocr Pathol. 2021;32:385–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Rivero A, Liang J. Sinonasal small cell neuroendocrine carcinoma: a systematic review of 80 patients. Int Forum Allergy Rhinol. 2016;6:744–51.

    PubMed  Google Scholar 

  116. Rooper LM, Bishop JA, Faquin WC et al. Olfactory carcinoma of the sinonasal tract: a distinctive neuroepithelial tumor pattern. Am J Surg Pathol. (Submitted).

  117. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022. https://doi.org/10.1007/s12022-022-09708-2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None. There has been no Grant support nor financial relationships pertaining to this manuscript.

Author information

Authors and Affiliations

  1. Department of Pathology, University Health Network, 200 Elizabeth Street, 11th floor, Toronto, ON, Canada

    Ozgur Mete

  2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

    Ozgur Mete

  3. Endocrine Oncology Site, The Princess Margaret Cancer Center, Toronto, ON, Canada

    Ozgur Mete

  4. Department of Pathology Moffitt Cancer Center, Tampa, FL, USA

    Bruce M. Wenig

Authors
  1. Ozgur Mete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce M. Wenig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozgur Mete.

Ethics declarations

Conflict of interest

The authors declare that this manuscript was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethics approval

Not applicable.

Informed Consent

The authors give consent for publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mete, O., Wenig, B.M. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head and Neck Pathol 16, 123–142 (2022). https://doi.org/10.1007/s12105-022-01435-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-022-01435-8

Keywords

Search

Navigation